Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...

Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...

FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

The true essence of Galentine's Day is all about bringing your besties together for a day filled with endless laughter, deep ...

Last week, the CNX SmallCap 100 index cracked by 7.3%. On Monday, it crashed a further 4%. The last time the index fell more than this was way back in December 2022 (8.33%). This serious decline comes ...

But do these positive changes reflect on the quality of care, and do patients benefit from AI and ML-powered solutions? In this article, I share my take on the transformative potential of AI and ...

The Register would like to point in the direction of a few. On December 15th 2024, developer Paul Sherman announced the end of the Absolute Linux project. This year, its website has already gone, but ...

Domino’s is cooking up a hefty deal for pizza lovers this week. The chain just announced a 50% discount on its famous pies, but the sale won’t be sticking around for long. Ready to cash in on ...

Discovery Chemistry, Evotec Ltd, Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.